Bacterial Therapy May Be Promising in Cancer Patients

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

A phase 2 study found a complete clinical response of 82% with neoadjuvant dostarlimab in dMMR solid tumors.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-G12D mutation.